%0 Journal Article %T Risk factors for therapeutic failure in the management of post-operative peritonitis: a post hoc analysis of the DURAPOP trial %+ AP-HP - Hôpital Bichat - Claude Bernard [Paris] %+ Physiopathologie et Epidémiologie des Maladies Respiratoires (PHERE (UMR_S_1152 / U1152)) %+ Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique (CIC 1425) %+ Centre Hospitalier Universitaire d'Angers (CHU Angers) %+ Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)) %+ CHU Rouen %+ CHU Pontchaillou [Rennes] %+ Hôpital Beaujon [AP-HP] %+ Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)) %+ CHU Amiens-Picardie %+ Simplification des soins chez les patients complexes - UR UPJV 7518 (SSPC) %+ Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier) %+ Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp) %A Montravers, Philippe %A Esposito-Farèse, Marina %A Lasocki, Sigismond %A Grall, Nathalie %A Veber, Benoit %A Eloy, Philippine %A Seguin, Philippe %A Weiss, Emmanuel %A Dupont, Hervé %A Trial Group, Durapop %A Bronchard, Régis %A Desmard, Mathieu %A Levrard, Mélanie %A Mahjoub, Yazine %A Gergaud, Soizic %A Gaillard, Thomas %A Plantefeve, Gaëtan %A Pajot, Olivier %A Blasco, Gilles %A Samain, Emmanuel %A Besch, Guillaume %A Pily-Floury, Sébastien %A Paugam, Catherine %A Pease, Sébastien %A Abback, Paer %A Girard, Claude %A Payen, Jean-Francois %A Herault, Marie-Christine %A Jaber, Samir %A Jung, Boris %A Delaye, Jean-Marc %A Gally, Josette %A Meistelman, Claude %A Perrier, Jean-François %A Asehnoune, Karim %A Cinotti, Raphael %A Tesnière, Antoine %A Mignon, Alexandre %A Lescot, Thomas %A Belhadj-Tahar, Nouria %A Beaussier, Marc %A Lepape, Alain %A Piriou, Vincent %A Wallet, Florent %A Tassin, Candice %A Cousson, Joel %A Raclot, Pascal %A Floch, Thierry %A Launey, Yoann %A Gouin, Philippe %A Clavier, Thomas %A Auboyer, Christian %A Collanges, Olivier %A Georger, Jean-François %< avec comité de lecture %@ 0305-7453 %J Journal of Antimicrobial Chemotherapy %I Oxford University Press (OUP) %V 76 %N 12 %P 3303-3309 %8 2021-12-01 %D 2021 %R 10.1093/jac/dkab307 %M 34458922 %Z Life Sciences [q-bio]/Human health and pathology/Infectious diseases %Z Life Sciences [q-bio]/Microbiology and Parasitology %Z Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyJournal articles %X Background Therapeutic failure is a frequent issue in the management of post-operative peritonitis. Objectives A post hoc analysis of the prospective, multicentre DURAPOP trial analysed the risk factors for failures in post-operative peritonitis following adequate source control and empirical antibiotic therapy in critically ill patients. Patients and methods Overall failures assessed post-operatively between Day 8 and Day 45 were defined as a composite of death and/or surgical and/or microbiological failures. Risk factors for failures were assessed using logistic regression analyses. Results Among the 236 analysed patients, overall failures were reported in 141 (59.7%) patients, including 30 (12.7%) deaths, 81 (34.3%) surgical and 95 (40.2%) microbiological failures. In the multivariate analysis, the risk factors associated with overall failures were documented piperacillin/tazobactam therapy [adjusted OR (aOR) 2.10; 95% CI 1.17–3.75] and renal replacement therapy on the day of reoperation (aOR 2.96; 95% CI 1.05–8.34). The risk factors for death were age (aOR 1.08 per year; 95% CI 1.03–1.12), renal replacement therapy on reoperation (aOR 3.95; 95% CI 1.36–11.49) and diabetes (OR 6.95; 95% CI 1.34–36.03). The risk factors associated with surgical failure were documented piperacillin/tazobactam therapy (aOR 1.99; 95% CI 1.13–3.51), peritoneal cultures containing Klebsiella spp. (aOR 2.45; 95% CI 1.02–5.88) and pancreatic source of infection (aOR 2.91; 95% CI 1.21–7.01). No specific risk factors were identified for microbiological failure. Conclusions Our data suggest a predominant role of comorbidities, the severity of post-operative peritonitis and possibly of documented piperacillin/tazobactam treatment on the occurrence of therapeutic failures, regardless of their type. %G English %Z DURAPOP trial group: Philippe Montravers, Regis Bronchard, Mathieu Desmard, Herve Dupont, Melanie Levrard, Yazine Mahjoub, Sigismond Lasocki, Soizic Gergaud, Thomas Gaillard, Gaetan Plantefeve, Olivier Pajot, Gilles Blasco, Emmanuel Samain, Guillaume Besch, Sebastien Pily-Floury, Catherine Paugam, Sebastien Pease, Paer Abback, Claude Girard, Jean-Francois Payen, Marie-Christine Herault, Sami Jaber, Boris Jung, Jean-Marc Delay, Josette Gally, Claude Meistelman, Jean-François Perrier, Karim Asehnoune, Raphael Cinotti, Antoine Tesniere, Alexandre Mignon, Thomas Lescot, Nouria Belhadj-Tahar, Marc Beaussier, Alain Lepape, Vincent Piriou, Florent Wallet, Candice Tassin, Joel Cousson, Pascal Raclot, Thierry Floch, Philippe Seguin, Yoann Launey, Benoit Veber, Philippe Gouin, Thomas Clavier, Christian Auboyer, Olivier Collanges, Jean-François Georger %2 https://hal.science/hal-03436464/document %2 https://hal.science/hal-03436464/file/2021%20Montravers%20et%20%20al.%2C%20Risk%20factoors.pdf %L hal-03436464 %U https://hal.science/hal-03436464 %~ INSERM %~ UNIV-PARIS13 %~ CNRS %~ UNIV-PICARDIE %~ APHP %~ UNAM %~ HL %~ COMUE-NORMANDIE %~ BS %~ UNIV-MONTPELLIER %~ SORBONNE-PARIS-NORD %~ UNIV-PARIS %~ UNIVERSITE-PARIS %~ UP-SANTE %~ PHYMEDEXP %~ U-PICARDIE %~ SSPC %~ UM-2015-2021 %~ TEST3-HALCNRS